Newsroom

Parexel has been nominated for the inaugural 2026 Prix Galien USA Patient First Award, a prestigious recognition celebrating excellence in clinical research and patient-centered care. Parexel’s nomination recognizes the work of Parexel and the Foundation Fighting Blindness. The inaugural Prix Galien USA Patient First Award recognizes organizations that embed patient voices into research and care delivery, advance equitable access and translate patient insights into meaningful improvements in health outcomes and quality of life.

Parexel was recognized as a World’s Top Disability Inclusive Business based on its high performance on the Disability Index®, the leading global benchmark for disability inclusion in business. This recognition reflects a company-wide commitment to creating an environment where colleagues and patients – regardless of physical ability or other differences – can participate and thrive in clinical research.

Parexel received a 2026 Triangle Business Journal (TBJ) Life Sciences Award in the Most Innovative Clinical Research Organization (CRO) category. These awards recognize individuals and organizations advancing innovation across the life sciences, including biotechnology, pharmaceuticals, clinical research, medical devices, diagnostics and human health. Parexel was recognized for our industry-leading clinical development impact, combining regulatory leadership, therapeutic expertise, AI driven innovation and meaningful Triangle community leadership that advances biomedical R&D.

Parexel was named the winner of the 2026 NEXT Award for Patient Leadership from Medidata Solutions. This award recognizes Parexel’s commitment to patient-focused technology and patient insights to improve the clinical trial experience and decrease burden on trial participants. Award winners were recognized at Medidata NEXT in NYC on March 11.